Want to see JP:4584 full AI Analyst Report?
4584 Stock Chart & Stats
¥203.00
¥2.00(1.89%)
At close: 4:00 PM EST
¥203.00
¥2.00(1.89%)
Day’s Range― - ―
52-Week Range¥125.00 - ¥363.00
Previous CloseN/A
Volume149.00K
Average Volume (3M)766.13K
Market Cap
¥7.18B
Enterprise Value¥11.31K
Total Cash (Recent Filing)¥3.29B
Total Debt (Recent Filing)¥2.55B
Price to Earnings (P/E)―
Beta1.08
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.28
Shares Outstanding50,582,990
10 Day Avg. Volume871,200
30 Day Avg. Volume766,126
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)7.17
Price to Sales (P/S)1.80
P/FCF Ratio-10.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)19.3
Revenue Forecast (FY)¥4.92B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained multi-year revenue expansion demonstrates the company has been able to commercialize products and gain market traction. This scale supports operating leverage potential, enables reinvestment in R&D and commercialization, and creates a firmer foundation for long-term growth despite episodic losses.
Positive Gross MarginMaintaining positive gross margins indicates core product economics cover direct costs, a durable advantage for a biopharma business. As sales scale, even compressed unit economics can translate into meaningful contribution margin, supporting SG&A and R&D funding and improving path to sustainable profitability.
Business Focus — Biosimilars/BiologicsA clear strategic focus on biosimilars and biologics positions the company in a structurally growing segment of healthcare. This specialization offers repeatable development and commercialization pathways, potential regulatory know-how build, and an addressable market that can support durable revenue streams as products advance.
Bears Say
Elevated LeverageHigh and previously extreme leverage raises refinancing and solvency risk for a company without steady profitability. Debt levels constrain strategic flexibility, increase interest burdens, and can force dilutive financing or curtailed investment in R&D or commercialization during adverse funding conditions.
Unstable Cash GenerationA swing from positive cash generation to significant cash burn signals weak operational resilience. Persistent or recurring negative operating and free cash flow elevates funding risk, may require external capital, and reduces the company’s ability to sustain long-term development programs without diluting shareholders or cutting investments.
Volatile ProfitabilityIrregular margins and episodic large losses indicate difficulty converting revenue growth into stable profits. This volatility undermines confidence in margin sustainability, complicates long-term planning, and increases the probability the company will need recurrent financing before achieving durable profitability.
Kidswell Bio Corporation News
4584 FAQ
What was Kidswell Bio Corporation’s price range in the past 12 months?
Kidswell Bio Corporation lowest stock price was ¥125.00 and its highest was ¥363.00 in the past 12 months.
What is Kidswell Bio Corporation’s market cap?
Kidswell Bio Corporation’s market cap is ¥7.18B.
When is Kidswell Bio Corporation’s upcoming earnings report date?
Kidswell Bio Corporation’s upcoming earnings report date is Aug 13, 2026 which is in 16 days.
How were Kidswell Bio Corporation’s earnings last quarter?
Kidswell Bio Corporation released its earnings results on May 14, 2026. The company reported -¥5.54 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Kidswell Bio Corporation overvalued?
According to Wall Street analysts Kidswell Bio Corporation’s price is currently Overvalued.
Does Kidswell Bio Corporation pay dividends?
Kidswell Bio Corporation does not currently pay dividends.
What is Kidswell Bio Corporation’s EPS estimate?
Kidswell Bio Corporation’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kidswell Bio Corporation have?
Kidswell Bio Corporation has 50,582,990 shares outstanding.
What happened to Kidswell Bio Corporation’s price movement after its last earnings report?
Kidswell Bio Corporation reported an EPS of -¥5.54 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.203%.
Which hedge fund is a major shareholder of Kidswell Bio Corporation?
Currently, no hedge funds are holding shares in JP:4584
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kidswell Bio Corporation
Kidswell Bio Corporation, headquartered in Tokyo, Japan, specializes in the development of pharmaceutical treatments for rare and complex diseases. The company, which was founded in 2001 and operated as Gene Techno Science Co.,Ltd. until rebranding in July 2021, maintains a robust pipeline of therapeutic candidates. This includes GND-004, designed for both ophthalmic conditions and oncology, and GND-007, aimed at immunological disorders. Their portfolio also features a range of antibodies being developed for cancer therapies. Further expanding its research, the GBS series encompasses GBS-001, GBS-004, and GBS-010 for oncology; GBS-005 for immunological diseases; GBS-007 and GBS-012 for eye-related ailments; GBS-008 for infectious diseases; and GBS-011 for renal conditions. Additionally, Kidswell Bio is progressing GCT-101 for alveolar clefts, GCT-102 for congenital isolated hypoganglionosis, alongside other investigational products addressing ophthalmologic disorders, cerebral palsy, peripheral nerve palsy, fractures, and spinal cord injuries.
Technical Analysis
Healios KK
―
StemRIM Inc.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―